View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Paclitaxel 175 / Carboplatin 5, Uterine Carcinosarcoma, adjuvant
Protocol-ID: 1600 V1.0 (Mini), PACL175/CRBP5, Carcinosarcoma of Uterus, adj.Indication(s)
- Endometrial Cancer; ICD-10 C54.1
Links
- Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer [clinicaltrials.gov]
- A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. [URL]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 01.08.2020